Publish with Us Search
Publish with Us

Cancer Immunology Connect

ISSN: 3078-154X

Eyad Elkord
Editor-in-Chief

Eyad Elkord
Editor-in-Chief

View Profile

Cancer Immunology Connect is a peer-reviewed, open-access journal focused on understanding the complex interactions between cancer cells and the immune system. It publishes innovative research on tumor immunology, cancer immunotherapy, and translational research to advance the fight against cancer through immunological approaches. The journal is available both in print and online, ensuring broad accessibility and dissemination of cutting-edge research to the global scientific community.

Volumes 1
Articles 6
Volume: 1, 2024
Submit Article Join Our Editorial Board Become a Reviewer
Download Flyer
Volumes

SCIFINITI ALERT!

Subscribe for research updates and exclusive content straight to your inbox

Open Access Policy:
All articles published in the journal Cancer Immunology Connect are made accessible through an open-access model, released under the CC BY license. This license facilitates the unrestricted dissemination of articles, encouraging widespread sharing and utilization of valuable research contributions.

Publication Charges:
No publication fee will be charged for articles published by December 2025, and all articles will be available as Open Access.

Subject Categories:
Cancer research, Immunology, Oncology

Article Template:
Please download the template for preparing your article according to our formatting standards. Using the template is recommended but not mandatory, our layout team will make any necessary adjustments after the manuscript has been accepted.

Target Audience:
Cancer Immunology Connect provides a platform for researchers, clinicians, and practitioners to share their findings, discuss challenges, and explore new frontiers in the fight against cancer through immunological approaches.

Ethics Statement:

All articles published by Cancer Immunology Connect adhere strictly to the ethical guidelines suggested by the Committee on Publication Ethics (COPE). We execute a stringent peer-review procedure that meticulously assesses the originality, quality, and precision of the research we disseminate. We employ advanced tools to scrutinize the legitimacy of submitted content and maintain a firm zero-tolerance stance toward instances of plagiarism, data manipulation, or inappropriate authorship. For further details, please review our comprehensive Publication Ethics and Integrity Guidelines.

Insights

More Insights

31 Days

Time to First Peer Review Decision

52 Days

Time to Final Acceptance

7 Days

Acceptance to First Online

Recent Updates

All Updates
Welcoming Dr. Eyad Elkord to Cancer Immunology Connect
2024-08-19
Announcing the Launch of Cancer Immunology Connect
2024-08-15

Recent Articles

All Articles
Research Article

Published: 15 Apr 2025

Association of Expression of Immune Checkpoints in Tumor-Infiltrating CD4+ T Lymphocytes with Disease-Free Survival in Colorectal Cancer Patients

Volume 1

https://doi.org/10.69709/CIConnect.2025.119991
Research Article

Published: 21 Mar 2025

Characteristics of Tumor Infiltrating Lymphocytes in Patients with Benign and Malignant Sinonasal Neoplasms

Volume 1

Introduction. Tumor infiltrating lymphocytes are a major component of sinonasal neoplasms, actively populating tumor tissue, yet their role remains poorly understood. The aim is to characterize subsets and functional profiles of tumor infiltrating lymphocytes in patients with benign and malignant sinonasal tumors. Materials and methods. Tumor infiltrating lymphocytes were isolated from the biopsy material of 58 patients: 18 with sinonasal..

https://doi.org/10.69709/CIConnect.2025.133891
Review Article

Published: 19 Mar 2025

Soluble Biomarkers as Predictors of Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)-Insights from the Tumor Microenvironment Perspective

Volume 1

Lung cancer is the major cause of mortality worldwide with non-small cell lung cancer (NSCLC) contributing to 85% of the cases. FDA-approved immune checkpoint inhibitors (ICI), anti-PD-1, and anti-PD-L1 are widely used as a standard treatment. However, the response rate is limited and is observed in only 20–40% of the patients. Therefore, predictive and prognostic biomarkers are needed to help..

https://doi.org/10.69709/CIConnect.2025.003399
Mini-Review

Published: 11 Feb 2025

CRISPR-Cas9 is Revolutionizing AML Treatment as a Novel Therapy

Volume 1

This review explores the progression of CRISPR-Cas9 genome editing technology in gene therapy for acute myeloid leukemia. Acute Myeloid Leukemia, a serious blood cancer, presents formidable treatment obstacles and a dismal prognosis. Effective treatments for acute myeloid leukemia rely on a clear understanding of its intricate genetic mechanisms, and CRISPR-Cas9 technology offers precision and adaptability for targeting the disease’s oncogenic..

https://doi.org/10.69709/CIConnect.2025.103019
Share
Help